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INTRODUCTION 
Data released by the Health and Family Welfare Ministry of India show that 
life expectancy for females is increased by five years, from 63.9 years in 2001-2005 to 
69.6 years in 2011-2015. In India, with the rise in life expectation in females, number 
of postmenopausal women is increasing. Approximately woman today, will live for 
about one third of her life, beyond menopause. 
Menopause is a normal physiological change wherein the permanent stoppage 
of menstruation takes place. Primarily menopause is due to loss of stocks of oocyte in 
ovary with a consequent fall in the level of hormones like oestrogen and progesterone. 
This results in the cessation of cyclical changes in the endometrium and hence 
menstruation. The loss of fertility and menstrual function that accompany menopause 
may have an impact on a woman’s sense of wellbeing.  
Women from fetal life till menopause experience different stages under the 
influence of female hormones. These hormones are secreted in very little quantity. 
According to different phases of her reproductive life, these hormones undergo a 
complex and ever changing trend.  
During menopause, woman passes from fertile to infertile stage. The oestrogen 
production is grossly reduced in postmenopausal period. It is due to the peripheral 
conversion of adrenal androgens and this occurs mainly in adipose tissue, liver and 
brain.  
Decrease in the level of oestrogen in postmenopausal period of females alter 
their general health by producing physiological, biochemical and structural changes. 
In a very significant way the body metabolism is affected. 
Lipid metabolism is affected by the level of oestrogen. Changes in serum lipid 
and lipoprotein levels indirectly lead on to coronary heart disease which determine the 
life expectation among postmenopausal women. 
According to Framingham study, morbidity rate due to coronary heart disease 
accelerate more quickly in females of age more than 45 years than in males. Before 
menopause, oestrogen protects females against coronary artery disease by its anti-
atherogenic effect. 
Altered serum lipid profile is associated with menopause and thus it is a major 
determining factor predisposing to cardiovascular diseases. It makes the screening of 
postmenopausal women for abnormal lipid profile mandatory. 
Significance of duration of menopause on serum oestradiol level and its 
correlation with lipid profile is to be investigated so that postmenopausal women can 
undergo further evaluation and earlier management. 
Hormonal alteration and the associated changes in serum cholesterol and 
lipoproteins level in relation to the duration of menopause is aimed to study at present 
so that specific health strategies can be promoted and thereby emerging cardiovascular 
diseases can be prevented among the postmenopausal women. 
AIM AND OBJECTIVES 
 
1. Estimation of serum oestradiol level in postmenopausal women and are divided 
into three groups based on the duration of menopause. 
2. Comparison of serum oestradiol level between these three groups. 
3. Estimation of lipid profile in the postmenopausal women included in these 
groups. 
4. Comparison of lipid profile values between the postmenopausal women of 
these three groups. 
5. Correlation of serum oestradiol level with the changes in lipid profile. 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
HISTORY 
Since biblical times, menstruation and menopause were dealt in our society. 
Even before the year 1800, references to menopause were found. Aristotle stated that 
menopause began even at the age of 40 years in females. The term “menopause” (la 
ménépausie) was coined by Charles Pierre Louis De Gardanne in 1821. 
Oestrogen is responsible for the development of the organs of reproductive 
system and secondary sexual characters in females. The name oestrogen is derived 
from the Greek word “oistros”, which means "verve or inspiration" and the suffix -
gen, means" producer of". The structure of oestrogen was determined by Adolf 
Butenandt in 1929 and was isolated by Edward Adelbert Doisy. The speed in 
hormonal drug research was increased thereafter.  
In 1930, Emmentin was discovered by Collip and Ayerst Laboratories. It was 
the oral oestrogen derived from urine of pregnant Canadian women. A drug company 
in Germany synthesised a product like that of Emmenin and German women with 
menopausal symptoms were treated with it.  
 For the treatment of menopausal symptoms, nonsteroidal oestrogen 
diethylstilbestrol (DES) was formulated by the British scientists. That was cheaper 
and more powerful. The Food and Drug Administration finally accepted it by the 
year 1938. 
The researches in modern lipid chemistry began in 17th century.  Earlier 
observations were made by Robert Boyle, Poulletier de la Salle and Antoine 
François de Fourcroy. Chevreul discovered many fatty acids during 19th century. 
He gave the name ‘cholesterine’ to the fat substances. The word ‘glycerine’ was also 
coined by him. He explained the components of fats. 
Lipoprotein structure and function were understood in detail in 20th century. 
Relationship of lipoproteins with disease states was investigated. The discovery of 
methods for the separation of lipoproteins like ultracentrifuge and the substances used 
for estimation of lipoprotein levels improved our knowledge about lipoprotein 
metabolism in normal and diseased state. 
In postmenopausal period, the hormonal changes like decreased level of 
oestrogen and markedly increased level of luteinizing and follicle stimulating 
hormone are seen which exert an important impact on lipid metabolism (Sacks F.M, 
A.M. Murray et al). According to genetic and epidemiologic studies, lipoprotein (a) 
can predispose to atherosclerosis. In 1963, Kare Berg discovered lipoprotein (a). In 
1987, human gene encoding apolipoprotein A was cloned. 
Cardiovascular disorders are the leading causes of death among females after 
menopause in developed world (Ariyo et al., 2002). Female hormones protect against 
the development of cardiovascular disease (Jeanes et al., 2007). Postmenopausal 
women are at particular risk for acquiring cardiovascular disorders (Schulz et al., 
2004). 
 FEMALE REPRODUCTIVE PHYSIOLOGY 
The female reproductive system is responsible for many important functions. 
The ova produced in ovaries are necessary for the reproductive function. In addition, 
they also produce sex hormones that maintain the reproductive cycle in females. 
Functional anatomy 
The important organs of reproduction in females are described as follows. 
 Vagina is also called as birth canal which meets the cervix. 
 Uterus is otherwise called womb which accommodates the growing baby. It 
has two parts: lower part is cervix which joins with vagina and upper part is 
called as body of the uterus or corpus. During pregnancy, size of the body of 
uterus increases which enable to accommodate the growth of the fetus. 
Through the cervical canal, sperms enter and menstrual blood comes out of the 
uterus. 
 The ovaries are present in the pelvic cavity and are connected to uterus on both 
sides with the help of various ligaments. They can produce ova and synthesis 
hormones during the reproductive period. 
 Fallopian tubes arise from the cranial part of uterus. Through these tubes ova 
are transported from the ovaries to uterus. Fertilization occur in the ampullary 
part of the tube. 
 
Development 
The mullerian ducts persist in females and they undergo further development. 
A portion of mullerian ducts fuse and form uterus and vagina. This fusion starts at the 
third month of intrauterine life. The fused walls form a septum which disappears later. 
The parts that do not fuse form the fallopian tubes on both sides. The ostia of fallopian 
tubes are present in the anterior portion of tubular invagination inside the peritoneal 
cavity. 
A ring-like constriction develops at about fifth month which demarcates the 
cervical position. After sixth month of gestation, thickening of the walls of uterus 
begins. 
The vagina is developed as a solid rod of epithelial cells and at the lower end of 
the uterus, a ring like outgrowth occurs which represents the developing vaginal 
fornix. By fifth month, due to the breakdown of central cells of the epithelium vaginal 
lumen is produced. The remains of the mullerian eminence represent the hymen. 
From the mesothelial layer of peritoneum, ovary is developed. During third 
week of intra uterine life, from the endodermal lining of yolk sac, the primordial germ 
cells get differentiated. By the fifth week, the germ cells migrate to the genital ridge 
and undergo mitotic division. Only by the seventh week of gestation, the primitive 
ovary can be distinguished from testis until then the gonads exist in an 
undifferentiated state.  
 
HORMONAL CHANGES AND MENOPAUSE 
Hormones are produced by the endocrine glands and they are secreted directly 
into blood. They are takenup by the target organs and other systems. Thereby 
hormones regulate the activities of target organs.  
As we grow older, natural changes occur in our body systems. Some target 
organs will have reduced sensitivity to their regulating hormone. The quantity of 
hormones synthesised may also change. The blood level of some hormones rise, some 
are reduced and some remain unchanged. Metabolism of hormones occur more slowly 
with increase in age. 
Most of the endocrine organs which secrete hormones are regulated by some 
other hormones. This regulation is also changed with age. For example, an endocrine 
organ may secrete less amount of hormone at an older age or it may secrete at a 
slower rate but the same amount. 
Female hormones 
The female gonads produce female sex hormones and are important to maintain 
the menstrual cycle in the reproductive period. Only when we understand the effects 
of hormones on body, mind and emotions, we will be able to decrease their negative 
effects and increase their positive effects in a better way.  
 
 
 Fetal life 
    From ovaries the oestrogen formation starts by 8 to 10 weeks of gestation. 
Oogonia develop from primary oocytes and about 6 to 7 million oogonia are present 
in ovary by fifth to sixth week of intra uterine life.  
Then the germ cells undergo atresia and at birth only 2 million oogonia remain. 
The gonadotrophic hormone levels are increased at birth and are decreased in 
childhood. 
 Puberty 
The physical maturation from a child to an adult which enable a female for 
sexual reproduction is called puberty. This is because of the hormonal signals from 
brain to ovaries. In response to the signals from brain, the ovaries produce female sex 
hormones that are responsible for the libido and development of brain, bones, muscle, 
blood, skin and breasts. Height and weight are increased in the first half of puberty 
and are finished after the complete development to an adult body. 
The onset of puberty vary from individual to individual and it is determined by 
genetic control of the signals from hypothalamus. This process is also influenced by 
some environmental factors which may play a permissive role. The age of menarche is 
influenced by health, genetic and socioeconomic factors (V.V. Khadilkar et al., 
2006).  
 
In India as per Agarwal's data, the age of menarche have reduced from  17 
years to 12.8 years. The average age of menarche is shown as 12.6 years in urban 
India. 
Even at birth every structure necessary for attaining puberty is present but our 
body system keeps it switched off for particular years. Only at the time of maturity, 
hormones which previously have been held in check start to exert their action on the 
body. 
           At puberty, the hypothalamo–pituitary–ovarian axis (HPO axis)  is activated 
leading to increased pulsatile secretion of gonadotrophin releasing hormone (GnRH) 
by hypothalamus that allows for increased secretion of follicle stimulating hormone 
(FSH), luteinizing hormone (LH) and oestradiol levels (Jiska S. Peper et al., 2009).                   
         An increase in oestrogen secretion from ovary exerts a positive feedback and 
there is a development of cyclical pattern of gonadotrophin secretion. 
 
 
              During reproductive period of females the menstrual cycle is controlled by 
five main hormones. Three hormones are secreted from brain and two other hormones 
are produced from ovaries. 
 Gonadotrophin releasing hormone is synthesised by hypothalamus. It reaches 
anterior pituitary and regulates the release of follicle stimulating hormone and 
luteinizing hormone. 
 Follicle stimulating hormone is released from anterior pituitary. It is transported to 
ovaries where it induces the growth of ova. 
 Luteinizing hormone is also released from anterior pituitary gland and it again is 
transported by the blood stream to ovaries. It helps in ovulation and in the formation 
of corpus luteum. 
 Oestrogen is synthesised by the developing ova. Oestrogen regulates the levels of 
gonadotrophin releasing hormone, follicle stimulating hormone and luteinizing 
hormone by feedback mechanism. It helps to prevent the formation of more than one 
ovum in each cycle. Oestrogen also helps in the development of female reproductive 
organs. 
 Progesterone is synthesised from ovary. It works along with oestrogen to increase the 
uterine thickening so that fertilised ovum can get implanted. It helps to increase the 
growth of breasts and helps in milk production. Level of progesterone also helps in 
regulating the release of gonadotrophin releasing hormone and gonadotrophins. 
 During puberty, the hypothalamo–pituitary–ovarian axis in females gets 
activated which helps the individuals to develop secondary sexual characters. The 
activation and deactivation of this axis also regulates the female reproductive cycles. 
Oestrogen at the time of puberty causes development of breasts and maturation 
of other reproductive organs. In females, it plays an essential part in growth spurt and 
fat distribution typically resulting in more deposition around the hips, buttocks and 
thighs. 
The ovaries also synthesis little amount of testosterone, a male hormone (Sang 
T et al., 1980). Testosterone increases growth of muscles and bones.  
 After puberty, follicle stimulating hormone, luteinizing hormone, oestrogen 
and progesterone all play a significant role in regulating the menstrual cycle. The 
menstrual cycles are irregular and anovulatory during the initial years and it implies 
that a maturation of the hypothalamo–pituitary–ovarian axis is needed. Regular 
cyclical changes result in ovulatory menstruation start only after adequate maturation 
of this axis (Buttram VC et al., 1975). 
 Reproductive period  
          The hypothalamo–pituitary–ovarian axis meant that hypothalamus, pituitary 
gland and ovaries act together. This axis has an important role in the development of 
our body systems like reproductive and immune systems and also it regulates the 
action of these systems. 
         The hypothalamo-pituitary system is involved in the control of gonadal 
development and reproductive rhythmicity (Guillemin et al., 1967; McCann and 
Porter et al., 1969; Frohman et al., 1973). This axis regulates the growth and 
reproduction in human beings.  
Gonadotropin releasing hormone expressing neurons present in hypothalamus 
secrete gonadotropin releasing hormone. Follicle stimulating hormone and luteinizing 
hormone are secreted from anterior part of pituitary gland. Oestrogen, progesterone 
and testosterone are produced from ovaries. The hypothalamo–pituitary–ovarian axis 
is having an important role in regulating the uterine and ovarian cycles in females.  
     The positive feedback loop between oestrogen and luteinizing hormone aids 
to produce follicles in ovary and ovulation. It also helps the uterus to thicken during 
implantation.  
When the ovum is released from follicle, the empty sac begins to synthesise 
progesterone which inhibit hypothalamus and pituitary gland. This stops the positive 
feedback loop between oestrogen and luteinizing hormone. 
In case of conception, the progesterone will be secreted by placenta; and so the 
mother cannot ovulate during pregnancy. If there is no conception, decreasing level of 
progesterone stimulate hypothalamus to start the secretion of gonadotropin releasing 
hormone again. These hormones control all the phases of menstrual cycle.  
Oestrogen accelerates the growth and development of female reproductive organs. 
It increases the vascularity, moisture and elasticity of vagina (Evan R et al., 1996). 
During the reproductive period of females, oestrogen protects the heart and bones. It 
also maintains the healthy state of breasts, uterus, vagina and bladder.  
           Other important female sex hormone is progesterone. When it is decreased, 
menstrual cycle and sexual function are affected. Decrease in the level of testosterone 
may reduce the libido in females. 
 
MENSTRUATION 
In reproductive period, females experience cycles of hormonal activity that 
repeat regularly at every month. With every cycle, the woman's body gets ready for a 
potential pregnancy even without her intention. The term menstruation means the 
periodic shedding of uterine lining. (Menstru means "monthly'') 
The menstrual cycle on an average takes about 28 to 35 days. Each cycle is 
divided into three phases depending on the events occurring in ovary and uterus. The 
phases of ovarian cycle are follicular phase, ovulatory phase and luteal phase. The 
phases of uterine cycle are menstruation, proliferative phase and secretory phase. 
Follicular phase of the menstrual cycle 
The events that take place during follicular phase are: 
 Follicle stimulating hormone and luteinizing hormone are secreted from pituitary 
gland and are transported to ovaries. 
 They stimulate the growth and development of ova inside the ovarian follicles. 
 They also stimulate the production of female sex hormone, oestrogen. 
 Increase in oestrogen level turns off the release of follicle stimulating hormone from 
pituitary by feedback mechanism. Balance between these hormones maintain the 
number of follicles that attain maturity. 
 During follicular phase, one of the follicles in one of the ovaries becomes dominant 
and attain full maturity. The development of other follicles are suppressed by this 
dominant follicle. Oestrogen is synthesised by the dominant follicle and other follicles 
die eventually. 
 
 
Ovulatory phase of the menstrual cycle 
          The ovulatory phase occurs at about 14
th
 day of the normal 28 days menstrual 
cycle. It occurs in the middle of menstrual cycle between follicular phase and luteal 
phase. The next menstrual cycle begins about two weeks later.  
The events occurring in ovulatory phase are 
 Increase in the level of oestrogen during follicular phase stimulates anterior pituitary 
gland to secrete more of luteinizing hormone. 
 This results in release of ovum from the dominant follicle of ovary. 
 As the ovum is released, it is captured by fimbrial end of the fallopian tubes which is 
transported along the tube. 
 The amount of mucus produced by the cervix is increased during this phase. In case of 
intercourse during this time, this mucus captures the sperm, nourishes it and helps it to 
move towards the ovum for fertilization. 
Luteal Phase of the Menstrual Cycle 
After ovulation, luteal phase begins and the events occur in this phase are: 
 Once ovum is released from the follicle, the empty follicle is transformed into corpus 
luteum. 
 The hormone progesterone is synthesised by corpus luteum which is essential for the 
implantation of fertilized ovum on the lining of uterus. 
 If ovum is fertilized by the sperm, it is transported through fallopian tube and get 
implanted in uterus. The woman is now pregnant. 
 If there is no fertilization of ovum, it passes down the uterus. There is no occurance of 
pregnancy. Breaking down and shedding of the lining of uterus occur which results in 
next menstruation. 
          Every hormone follows its own pattern of increasing and decreasing trend in 
different phases of the menstrual cycle but altogether they form a predictable chain of 
events. One mature ovum is released from the ovary in every cycle and it passes down 
the fallopian tube to reach uterus.  
       If that ovum is not fertilised, the secretion of oestrogen and progesterone by ovary 
is decreased. When the action of these hormones is less, uterine lining is filled with 
blood and shed resulting in menstruation. 
PREGNANCY 
If the ovum released during ovulatory phase is fertilised, pregnancy results. 
Level of female sex hormones change dramatically. At the end of cycle there will be a 
normal fall in the level of oestrogen and progesterone which does not occur in case of 
pregnancy so no menstruation is seen. 
Human chorionic gonadotrophin, a new placental hormone is produced and it 
stimulates the ovaries of mother to secrete a large amount of oestrogen and 
progesterone which are needed to maintain pregnancy.  
The placenta takes over the function of producing oestrogen and progesterone 
from ovaries by the end of fourth month of gestation. 
The hormones oestrogen and progesterone increase the thickening of uterine 
lining and also the circulating blood volume. They relax the uterine muscles to make 
sufficient space for the fetus to grow. 
Progesterone and another hormone called relaxin increase the relaxation of 
ligaments, joints and muscles. Increase in the joint mobility of the pelvic girdle will 
increase the pelvic capacity so that the baby can pass through it during parturition. 
During delivery of the baby, many other hormones come into play and help in 
uterine contraction. They also stimulate breast milk production and ejection after the 
childbirth. 
AFTER CHILDBIRTH 
After the delivery of baby, level of female sex hormones falls sharply. This 
results in many physical changes in mother. The uterine size decreases to its previous 
non-pregnant size, improvement in the tone of pelvic floor muscle and the blood 
volume becomes normal. 
 The Menopause 
Again significant change in hormonal levels occurs in females around the time 
of last menstrual period. The normal functioning of ovaries starts to deteriorate at 
about five to ten years before the woman's last period. Menstrual cycle may become 
quite erratic. Bleeding may become heavier or lighter and the cycle may either be 
shorter or longer (Santoro N et al., 1996). 
  Changes around the years of menopause are due to the changing levels of 
hormones mainly oestrogen synthesised by ovaries. There is an irregular decrease in 
the level of oestrogen during perimenopause. 
In males, the hypothalamo-pituitary-gonodal axis once activated continues to 
function for the rest of their life. But in females, it becomes deregulated in later life 
leading to menopause. This deregulation is mainly due to lack of oocytes which 
synthesis oestrogen so that the positive feedback loop cannot be maintained. 
As the age of women increases, hypothalamo-pituitary-ovarian axis activity 
decreases and women can no longer be fertile (Reyes FI et al., 1997). 
  In postmenopausal women, ovary secretes androgens but virtually no oestrogen 
(Grodin J.M et al., 1973). Eventhough the ovary contain some oocytes, the follicles 
are not capable of responding to gonadotropins and producing oestradiol. After 
menopause, the oestrogen is produced mainly due to the peripheral conversion of 
androgens from adrenal gland. It occurs in peripheral adipose tissue and also in liver, 
kidney, brain etc (Longcope C et al., 1978).  
Very little oestrogen is produced by ovaries so that the uterine lining is failed 
to thicken up and this results in stoppage of menstruation. Physiological levels of 
oestradiol selectively potentiate endothelium dependent vasodilation in healthy 
postmenopausal women (David M. Gilligan MD et al., 2015). 
The normal age of attaining natural menopause is earlier in India at about 44 
years (Ringa V. et al., 2000). Sometimes, the ovaries stop working at an earlier age 
even before the age of 40 years and this condition is called premature ovarian failure. 
This condition affects about 1% of females. 
Menopause is defined to occur if a female had no menstrual bleeding for 
twelve months continuously. This can also be explained by a decreased synthesis of 
female sex hormones by ovaries. Marked deficiency of oestrogen is seen in the body 
of woman just before and after menopause. It can therefore produce some detrimental 
effects on her health. 
During transitional period of menopause, the menstrual cycles become 
irregular. The interval between each cycles vary from one another. There is a gross 
fluctuation in the level of hormones. Ovulation does not occur in every menstrual 
cycle. Usually the date at which last menstrual period occurred is considered as 
menopause. 
In a woman’s life, menopause is a normal physiological alteration and need not 
be a diseased state. The transition of menopausal period has various effects on the 
health of a woman and can produce lot of symptoms. The phases of menopausal 
transition can be classified by the bleeding pattern said by the woman. 
We can assess the impact of menopausal effects on the life of women by 
Greene Climacteric Scale questionnaire devised by Greene JG (1998), Cervantes 
Scale (Monterrosa-Castro A et al., 2012) and the Menopause Rating Scale 
(Chedraui P et al., 2010). 
 Premenopause 
The years just before the last menstrual period is termed as premenopause. At 
this time the level of female sex hormones has become more variable and there is a 
presence of effects of hormone withdrawal on target organs (Harlow SD., et al 2012). 
Premenopause usually begins some years before the irregular menstrual cycles. 
 Perimenopause 
The meaning of "perimenopause" is "around the menopause". It means the 
years of menopausal transition which is a period of time that precede and follow the 
last menstrual period.  
According to the North American Menopause Society, this menopausal 
transition presents for about four years. The Centre for Menstrual Cycle and 
Ovulation Research explains this transition as a period of six to ten years resulting in 
menopause at the end. 
In perimenopausal period, the level of oestrogen is about 20–30% higher than 
in premenopausal period but with wide fluctuations in its level. During 
perimenopausal and postmenopausal period these hormonal fluctuations produce 
many of the physical changes in females (Chichester et al., 2011).  
The changes like hot flushes, difficulty in sleeping, night sweats, vaginal 
dryness, urinary incontinence, osteoporosis and cardiac disease are due to changes in 
the level of hormones. 
In this period fertility decreases but we cannot consider this to reach zero until 
menopause has occurred officially. The date of official menopause can only be 
determined retrospectively. Only when one year have completed after the final date of 
menstruation, we can declare menopause. 
Even around the age of 35 years signs and symptoms of menopausal transition 
start. Although many women experience the effects of transition in the age of forty, 
this is about many years after the real beginning of perimenopausal period.  
The period of this menopausal transition and the effects experienced can be just 
a few years or it may extend even to ten years. The time period and severity of effects 
menopausal transition for any postmenopausal woman cannot be predicted earlier. 
Even though the course and effects of menopausal transition is unpredictable, 
the age of perimenopause is predictable to some extent. Women usually experience 
these perimenopausal symptoms at about the same range of age as their mother did 
(Kessenich et al., 2013). 
Some studies show that melatonin supplementation in women of menopausal 
transition can increase their gonadotropin levels and function of thyroid gland. In 
some women it can even restore the fertility and can prevent the menopause 
associated depression (Bellipanni G et al., 2005). 
 Postmenopause 
The term "postmenopausal" refers to women who have not experienced any 
menstrual period for atleast twelve months, even though they still have uterus and are 
not pregnant or lactating (Harlow SD et al., 2012).  
In women after the surgical removal of uterus, postmenopausal change can be 
diagnosed by a very high level of follicle stimulating hormone in their blood.  
Thus in a woman's life, postmenopause is considered to occur after twelve 
months of her last menstrual period and by that time her ovaries become inactive. 
MENOPAUSAL SYMPTOMS  
 Hot flushes:  
                  The most important and common symptom of menopause is hot flushes 
seen in about 75% of perimenopausal women. This symptom vary among the 
postmenopausal women. Hot flush is a feeling of warmth experienced by the women 
which spreads all over the body and lasts for about 30 seconds to a few minutes. 
             Often hot flushes are accompanied by palpitations, flushed skin and sweating. 
It increases the temperature of body and pulse rate. It can result even insomnia. Hot 
flushes can last for about 2 to 3 years but women may experience them for more than 
5 years. 
 Urinary incontinence and burning micturition 
 Changes in vagina: 
Due to decreased oestrogen level, perimenopausal women may experience pain 
during intercourse because of vaginal atrophy and decrease in vaginal discharge. 
 Changes in breasts: The shape of breasts may be changed after menopause. 
 Skin thinning 
 Weight gain: 
                A three year study conducted in healthy postmenopausal women show an 
average increase in weight of about five pounds. 
 Osteoporosis: 
                Bone loss is rapid and common after menopause. Peak bone density is 
reached by females at the age of about 25 to 30 years. After that age loss of bone 
averages as 0.13% per year. During perimenopause, loss of bone is accelerated for 
about 3% per year. This bone loss can result in osteoporosis, a condition which 
increases the risk of fracture in bones. These bone fractures are intensely painful and 
can affect the day to day activities. 
 Cardiovascular disease: 
                  Although it is not well defined how much of risk to develop heart disease 
is due to ageing and how much is due to the hormonal changes of menopause. Women 
who underwent premature menopause or surgical menopause at a younger age have an 
accelerated risk of developing cardiac disorder. 
              Hormonal changes in women after menopause may contribute to the 
development of depression, mental irritability and poor concentration. But the 
menopause need not be a disastrous time with unpleasant symptoms for every woman. 
Treatments such as hormone replacement therapy can be effective (Col NF et al., 
1997). 
So in every woman's life, from the cradle to grave hormones play an important 
role. 
 
 
 
 
 
 
 
 
 
 LIPIDS AND LIPOPROTEINS 
Lipids play an important role in every aspect of biological life. They are the 
basic structural components in all human cells. They are involved in many of the 
metabolic pathways. Lipids are the organic compounds which are water insoluble but 
miscible in organic solvents. The study of lipid metabolism is called as Lipidology.  
Cholesterol 
Cholesterol is a steroid substance found only in animals. It is present in every 
cell of the body. It is a precursor of various biological substances including steroid 
hormones and bile acids. Cholesterol esters are formed from the plasma cholesterol 
which is esterified with fatty acids. 
According to WHO Report 2002, factors which increase the risk of 
developing diseases are high blood pressure, alcohol consumption, tobacco 
consumption, deficiency of iron, unsafe water, underweight, high cholesterol, smoke 
from fuels, obesity, sanitation and hygiene (Chockalingam et al., 2006). 
Lipoproteins 
As lipids are insoluble in water media, they have to be transported in body 
fluids with the help of spherical soluble protein complexes which are called 
lipoproteins.  
Lipids can be derived from food called exogenous lipids or synthesized in our 
body called endogenous lipids. The inner core with water insoluble triglycerides and 
cholesterol esters is surrounded by the water soluble group of proteins, phospholipids 
and free cholesterol. 
The function of lipoprotein particles is to transport triglycerides and cholesterol 
in the blood stream to all tissues. The most common tissues are the liver and adipose 
tissue. All our body cells rely on cholesterol to use as building-blocks in the synthesis 
of cell membranes. It helps to control the water content and water soluble substances 
inside the cell and also to construct their internal structure and cellular enzymes. All 
lipoprotein particles are synthesized in liver and small intestine but interestingly not in 
adipose tissue.  
Most of the enzymes, structural proteins, transporters, antigens, toxins and 
adhesins are lipoproteins. Examples are the plasma lipoprotein particles which are 
classified into high and low density lipoproteins, bacterial lipoproteins and 
transmembrane proteins present in mitochondria. 
Structure 
The hydrophilic groups of the lipoprotein particles are phospholipids, 
apoproteins and cholesterol which are faced outward. This property make them 
soluble in the aqueous medium like blood. Internally they carry triglycerides and 
cholesteryl esters which are shielded from water by the apoproteins and single layer of 
phospholipid. 
The addition or removal of triglycerides and cholesterol from lipoprotein 
transport particles is determined by proteins forming the surface of particles. 
Development of atheroma depends upon the pattern of cholesterol transport and not 
on the concentration of cholesterol itself. 
 Classification 
Depending upon the buoyant density, lipoproteins are classified. The density is 
inversely related to their size. When lipid to protein ratio is greater, larger the size and 
density is less. Lipoproteins are classified into five major classes.  
1. Chylomicrons  
They are the largest lipoproteins with least density. Their function is to 
transport lipid which are exogenous, from gut to all other cells. 
2. Very low density lipoproteins 
These lipoproteins transport endogenous lipid from liver to other cells. 
3. Intermediate density lipoproteins  
They are produced when very low density lipoproteins are converted to low 
density lipoproteins. They are transient and do not usually present in plasma. 
4. Low density lipoproteins 
They are produced from very low density lipoproteins. They transport 
cholesterol to cells. 
5. High density lipoproteins 
  They are the lipoproteins with maximum density. Their function is to 
transport cholesterol back to liver from peripheral cells. This process is called reverse 
cholesterol transport. 
 
 Metabolism 
                 The changes that occur in the lipoprotein particles inside our body is called 
as lipoprotein metabolism. Metabolism of lipoproteins take place by two pathways. In 
exogenous pathway, the metabolism of lipoprotein particles occur which are derived 
from dietary or exogenous lipids and in endogenous pathway, the metabolism of 
lipoprotein particles occur which are originated in liver through de novo synthesis of 
triacylglycerols or so called endogenous lipids. 
The cells of liver are the main platform for the metabolism of triacylglyerols 
and cholesterol. Some amounts of triacylglycerols and glycogen are stored in 
hepatocytes. But the main storage cells are adipocytes for triacylglycerols which do 
not synthesis any lipoproteins. 
 
Exogenous pathway 
During absorption of fat, emulsification of fats present in chyme is by bile. 
Then triacylglyceride molecules are cleaved into two molecules of fatty acids and one 
molecule of 2-monoacylglycerol by pancreatic lipase. These small molecules can 
easily be absorbed by the intestinal cells. Inside of the intestinal cells, 
triacylglycerides are again formed from fatty acids and monoacylglycerides. 
The lipids like triacylglycerols, cholesterol, cholesteryl esters and 
phospholipids are attached with apolipoprotein B-48 and form nascent chylomicrons. 
These chylomicrons are secreted into villous lacteals. This process depends mainly on 
the presence of apolipoprotein B-48.  
As the nascent chylomicrons particles passes in the lymphatic system they 
bypass the hepatic circulation. They reach the bloodstream through the thoracic duct. 
In the blood stream, they interact with high density lipoprotein particles. 
Apolipoprotein E and apolipoprotein C-II are donated from high density lipoproteins 
to the nascent chylomicrons and convert the chylomicrons to a mature stage. 
The enzyme lipoprotein lipase present on endothelial cells of the blood vessels 
is activated by these mature chylomicrons through apolipoprotein C-II. 
Triacylglycerol present in chylomicrons is hydrolysed by lipoprotein lipase, glycerol 
and fatty acids are released. The peripheral tissues like adipose tissue and muscle 
absorb this glycerol and fattyacids and are utilised for energy or storage. 
After hydrolysis, the chylomicrons are now termed as chylomicron remnants. 
These chylomicron remnants circulate in bloodstream until they are taken up by liver. 
It is due to the interaction of apolipoprotein E with the receptors for chylomicrons 
present in the surface of liver. 
This interaction results in the endocytosis of chylomicron remnants and are 
hydrolyzed by hepatic lysosomal enzymes. Glycerol and fatty acids are released into 
the cell by this lysosomal hydrolysis and this can be utilised for energy. It can also be 
stored for later use. 
Endogenous pathway 
Liver is the main platform for lipid metabolism as it can store glycerols and 
fatty acids in its cells. Hepatocytes can also synthesis triacylglycerols de novo. By 
using cholesterol they synthesis bile. 
       In liver, nascent very low density lipoproteins particles are formed from 
cholesteryl esters and triacylglycerols and are attached with apolipoprotein B-100.  
The release of these particles into bloodstream depends upon the presence of 
apolipoprotein B-100. 
Nascent very low density lipoproteins interact with high density lipoproteins in 
the blood stream. This results in the donation of apolipoprotein C-II and 
apolipoprotein E from high density lipoproteins particles to nascent very low density 
lipoproteins. 
Once the apolipoproteins C-II and E are attached with nascent very low density 
lipoproteins they become mature. Very low density lipoprotein particles are then 
circulate in blood and encountered by the enzyme lipoprotein lipase present in the 
endothelial cells. 
The very low density lipoprotein particles are hydrolyzed by                      
lipoprotein lipase, glycerol and fatty acids are released. Apolipoprotein C-II activates 
this process. Glycerol and fatty acids can be absorbed from blood by the tissues like 
adipose tissue and muscle.  
Once hydrolyzed very low density lipoproteins are named as very low density 
lipoprotein remnants or otherwise called intermediate density lipoproteins. These very 
low density lipoprotein remnants circulate in blood until apolipoprotein E interact 
with the remnant receptors present in liver where they can be hydrolyzed by the 
enzyme hepatic lipase. 
Hydrolysis of very low density lipoprotein remnants by hepatic lipase releases 
fatty acids and glycerol leaving behind intermediate density lipoprotein remnants. 
They are called low density lipoproteins which have more cholesterol concentration 
(Kumar, Vibhor et al., 2011). 
Circulating low density lipoproteins are absorbed by the hepatocytes and other 
cells. Low density lipoproteins bind to their target tissue by an interaction between the 
low density lipoprotein receptors in liver and other cells with apolipoprotein B-100 
present on low density lipoprotein particles.  
In liver through endocytosis absorption occurs and the internalized low density 
lipoproteins are hydrolyzed by the lysosomes of hepatocytes and lipids are released 
mainly cholesterol. 
Lipoproteins are associated with the proteins called apolipoproteins (apo). 
ApoA is associated with high density lipoprotein particles and the subtypes are 
apoA1and apoA2. In apoB series, apoB100 is very important seen in low density 
lipoprotein particles which acts as a ligand for low density lipoprotein receptor.  
In general lipid levels in normal range is needed to maintain a healthy cardiac 
function and to decrease the risk of developing cardiac disease or stroke. Individual 
components of a lipid profile with other known risk factors increase the overall risk of 
causing cardiovascular disease in a person. 
In 2002, the National Cholesterol Education Programme (NCEP) Adult 
Treatment Panel III suggested the guidelines for evaluating the lipid levels and to 
decide the management accordingly. 
 
 
PHYSIOLOGY OF OESTROGEN 
               There is a close association between the female sex hormone, oestrogen and 
the emotional wellbeing of a female. Oestrogen is a vital hormone essential for the 
proper functioning of our body. Our body needs oestrogen in its natural form. Only 
then it can function normally without being interfered by other hormones like 
progesterone. 
 
At the time of puberty, the ovaries of a female start releasing oestrogen in 
coordination with the menstrual cycle. Around the middle of cycle, level of oestrogen 
increases suddenly stimulating the release of an ovum and then it decreases quickly. 
During other days of the month there is a gradual rise and fall in the level of 
oestrogen. There is a wide variation of oestrogen levels present in a same woman on 
different days of the cycle and between two different women on the same day of their 
menstrual cycles. 
Types 
In women, oestrogens are present in three forms. They are oestrone, oestradiol 
and oestriol. During reproductive period oestradiol is considered as the predominant 
oestrogen having increased serum levels as well as increased oestrogenic activity. 
After menopause, oestrone is the predominant oestrogen and during the time of 
pregnancy, oestriol is the predominant oestrogen in our circulation. 
 
The amount of oestriol is more out of the three oestrogens but it is the weakest. 
Strongest oestrogen is oestradiol whose potency is about 80 times more than that of 
oestriol (Files JA et al., 2011). 
Thus the most important oestrogen is oestradiol in non-pregnant females during 
reproductive period. But during pregnancy, oestriol is more important and oestrone is 
the primary form of oestrogen in postmenopausal women. 
 
 Biosynthesis  
         All the three different forms of oestrogen are produced from androgens 
especially testosterone and androstenedione by the action of aromatase. In females, 
oestrogens are synthesised mainly by ovaries and at the time of pregnancy, placenta is 
the main site of production of oestrogen. Oestrogen production is stimulated by 
follicle stimulating hormone which acts on the granulosa cells of ovary and corpus 
luteum.  
Smaller amount of oestrogens are also produced by the tissues such as liver, 
breast, adipocytes and adrenal glands. This peripheral synthesis of oestrogen is 
particularly important in women of postmenopausal period (Nelson LR et al., 2001). 
In females, oestrogen synthesis starts from the theca interna cells of ovary 
where the androstenedione is synthesised from cholesterol. A weak androgen, 
androstenedione is a precursor for other more potent forms of androgens like 
testosterone and also for oestrogen.  
Androstenedione crosses the basal lamina of granulosa cells. Here it is 
converted immediately into either oestrone or testosterone and then oestradiol is 
formed in an additional step. The enzyme 17β-hydroxysteroid dehydrogenase converts 
the androstenedione to testosterone. Aromatase converts the androstenedione into 
oestrone and testosterone into oestradiol. These enzymes are expressed only in the 
granulosa cells of ovary. 
In granulosa cells 17α-hydroxylase and 17, 20-lyase are not present.  In theca 
cells these enzymes and 17β-hydroxysteroid dehydrogenase are expressed but they 
lack the enzyme aromatase. Therefore the presence of both granulosa cells and theca 
cells are mandatory for the synthesis of oestrogen in ovaries.  
 
 
Mode of action 
Oestrogens, like any other steroid hormones can easily diffuse through the cell 
membrane. After getting inside the cell, they combine with and activate the oestrogen 
receptors. They form a dimeric nuclear protein which binds to DNA and regulates 
gene expression. In addition oestrogens combine with rapid signalling membrane 
oestrogen receptors and activate them (Soltysik K et al., 2013). 
In our cells, the expression of oestrogen receptors determines the actions of 
oestrogen. The oestrogen receptor is present specifically in organs like uterus, ovary 
and breast. In postmenopausal women, the genetic polymorphic characters of 
oestrogen receptor are associated with the metabolic effects of oestrogen (Darabi M 
et al., 2011). 
 Functions 
1. Structural 
i. Development of female secondary sexual characters 
ii. Elevated lipid store 
iii. Potentiate the growth of the endometrium 
iv. Stimulate the growth of the uterus 
v. Maintain the integrity of the vessel wall 
vi. Increase the formation of bone and reduce its resorption 
2. Reproductive function 
a. Uterus  
Oestrogen along with progesterone prepares the uterine lining so that the fertilized 
ovum can be implanted. It increases oxytocin receptors present in the myometrium. 
b. Ovary 
Increase in oestrogen level stimulates the anterior pituitary to release luteinizing 
hormone which results in ovulation. 
 
 
c. Libido 
Libido is dependent on androgen levels (Warnock JK et al., 2005) only in the 
presence of oestrogen.  
3. Metabolism 
a. Protein                                                                                                               
 Increase in hepatic production of binding proteins 
b. Lipid 
By antioxidant effect it prevents LDL oxidation and atherosclerosis                                     
Enhances LDL clearance by increasing hepatic LDL receptor expression. 
Reduces hepatic lipase and increases HDL level 
4. Coagulation 
Increase in the level of plasminogen and clotting factors II, VII, IX, X                         
Decrease in the level of antithrombin                                                            
Increase in adhesiveness of platelets 
5. Water balance 
Retention of sodium and water 
Increase in the level of sex hormone binding globulin and cortisol 
6. Alimentary system 
Decrease in motility of bowel 
Increase in cholesterol concentration of bile 
 
7. Melanin 
Elevate pheomelanin and decrease eumelanin levels 
 
8. Malignancy 
Induce breast cancers which are hormone-sensitive 
9. Respiratory system 
Support alveoli and controls respiratory function  
10.  Development of breast  
Oestrogen together with growth hormone and insulin like growth factor-1 is 
essential for the development of breast at the time of puberty and also the maturation 
of breast at the time of pregnancy and lactation. 
Oestrogen causes development of ductal component of the breast and it also 
induces deposition of fat and growth of connective tissue. It indirectly influences the 
development of lobuloalveolar component by promoting the expression of 
progesterone receptors.  
Prolactin secretion is also induced by oestrogen. During pregnancy, prolactin 
along with oestrogen and progesterone increases the lobuloalveolar development of 
breast (Blackburn S et al., 2014). 
11.  Skin 
Oestrogen promotes the collagen content, increases the thickness of skin and 
improves the vascularity of skin. Oestrogen acts through the oestrogen receptors 
present on human skin.  
      The different numbers of oestrogen receptors are present in different body 
parts. More number of receptors are seen on the skin over face, thigh and breast. 
12.  Cardiovascular disorders 
Oestrogen prevents atherosclerosis in younger women by its vasculo protective 
action and thereby protects against cardiovascular disorders (Rosano GM et al., 
1999). 
Due to its antioxidant property it fights against infections and protects arteries 
from oxidative damage. This again lowers the risk of developing cardiovascular 
diseases. 
13.  Cognitive function 
Verbal memory score is a reliable measure to test the level of cognition. These 
scores in directly related to the oestrogen level in females. 
Oestrogen if administered immediately after menopause, it prevents any 
reduction in the verbal memory (Hara Y et al., 2015). 
14.  Immunity 
Oestrogen by its anti-inflammatory action helps to mobilise the neutrophils 
(Sherwin BB et al., 2012). 
15.  Psychology 
Oestrogen has a significant role in the mental health of females. Sudden 
decrease in the level of oestrogen in postpartum, withdrawal of oestrogen in 
perimenopause and sustained low levels of oestrogen in postmenopause correlate with 
significant lowering of mood (Lasiuk GC et al., 2007). 
 
Therapeutic uses 
 Hormonal contraception 
Most of the oral contraceptives used to prevent pregnancy contain a synthetic 
oestrogen and progestin. Because increased level of circulating oestrogen can 
reduce the levels of follicle stimulating hormone and luteinising hormone by 
negative feedback.  
 Hormone replacement therapy  
                Lack of oestrogen in women after menopause can accelerate the risk 
of heart disease (Sarrel PM et al., 1989). To treat the menopausal symptoms 
such as hot flushes, urinary incontinence, vaginal dryness, chilly sensations, 
fatigue, dizziness, sweating and mental irritability oestrogen can be suggested 
to postmenopausal women. 
                 It can also be used to prevent osteoporosis. Oestrogen therapy 
decreases the fractures of spine, hips and wrist by about 60% and increases the 
bone density of spine by 5% in postmenopausal women who are treated within 
three years of the duration of menopause. 
                  Oestrogen replacement therapy also decreases serum cholesterol 
level. If it is started immediately after menopause it may lower the 
development of coronary heart disease. Oestrogen also protect from 
atherosclerosis by lowering the level of low density lipoproteins and 
triglycerides, increasing high density lipoproteins, properties of vasodilatation 
and anti-inflammatory effect. 
 
 Miscellaneous 
              In humans, oestrogen promotes wound healing (Oh DM Phillips et 
al., 2006). Oestrogen is also used to treat dryness of vagina, amenorrhoea, 
dysmenorrhoea and oligomenorrhoea. Oestrogen can be used as a lactation 
suppressant. 
Side effects 
Increased level of oestrogen is seen after exogenous administration in 
oestrogen therapy or due to physiological conditions like pregnancy. There is an 
increased risk of thrombosis expected in any of the above situation (Mitchell RS et 
al., 2007). Report from Woman’s Health Initiative suggested an elevated risk of 
developing deep vein thrombosis and cerebrovascular disease in postmenopausal 
women after the age 50 years who are on hormone replacement therapy. 
In cirrhosis of liver, metabolic function is decreased leading to palmar 
erythema and spider angioma due to excess of oestrogen. 
 
 
 
 
 
 
EFFECT OF OESTROGEN ON LIPID PROFILE 
Gy, AD Blann et al., 1997 studied the alteration in lipoprotein levels during 
perimenopause and correlated with the level of oestrogen.  Oestrogen increases the 
level of high density lipoproteins by decreasing the hepatic lipase activity which 
catabolizes the high density lipoproteins. Oestrogen decreases the oxidation of low 
density lipoproteins and increases the hepatic expression of low density lipoprotein 
receptors thereby decreasing the level of low density lipoproteins by accelerating the 
clearance. The alteration in lipid and lipoprotein values in postmenopausal women 
towards atherogenicity is due to the deficiency of oestrogen. 
Cardiovascular disease are uncommon in women until their menopause. The 
delay in the development of cardiovascular disease expression in women compared 
with men is possibly as a result of the protective effects of oestrogen during the 
reproductive years of a woman. 
Nurses’ Health Study states that in women who underwent surgical 
menopause by bilateral oophorectomy and not provided with oestrogen replacement, 
the chance of developing coronary heart disease is twice as that of the women who 
received oestrogen therapy after surgery (Colditz GA et al., 1987). 
 According to the population based observational study report, favourable 
results of oestrogen therapy are seen on cardiovascular disease and this led to its 
extensive use by the women after menopause. 
In premenopausal women, low density lipoprotein levels are less and high 
density lipoprotein levels are more when compared with same age group men. In 
postmenopausal women, low density lipoprotein levels rise and even exceed those of 
age matched men and there is a fall in the high density lipoprotein levels (Campos H 
et al., 1988). 
According to Tikkanen MJ et al., in 1978, oral oestrogen decreases low 
density lipoproteins level and elevates the level of low density lipoproteins in 
postmenopausal women whose baseline lipid values are normal. 
The decrease in low density lipoproteins level may be due to the increased 
conversion of cholesterol to bile acids in liver and accelerated expression of low 
density lipoprotein receptors over the surface of hepatocytes which results in 
increased clearance of low density lipoproteins from blood.  
The rise in high density lipoproteins level may be due to increased synthesis of 
apolipoprotein A-I and reduced hepatic lipase activity and thereby increase in the 
level of HDL2. This high density lipoprotein subparticle is more active in reverse 
cholesterol transport. 
Very low density lipoproteins level may increase due to the enhanced synthesis 
of apolipoprotein B and triglycerides. But these particles may not have much of 
atherogenic potential (Walsh BW et al., 1991). 
 
Oestrogen replacement therapy also reduces the levels of lipoprotein (a) which 
is a lipoprotein having structural similarity with low density lipoprotein and 
plasminogen. This is supposed to have antithrombolytic and proatherogenic 
properties. The concentration of lipoprotein (a) increases after menopause. 
Lipoprotein (a) which is considered as an independent predisposer for cardiovascular 
diseases is controversial (Ridker PM et al., 1993). 
Secondary prevention cholesterol reduction trials suggest that the favourable 
effect of oral oestrogen on lipoproteins is it could decrease the development of 
atherosclerosis and its acute sequelae (Levine GN et al., 1995).  
According to Lipid Research Clinic Follow-up Study in postmenopausal 
women the effects of oestrogen on lipoproteins were not fully responsible for the 
decrease in cardiovascular deaths. 
The guidelines released by the American College of Physicians for oestrogen 
therapy stated that “Women who have coronary heart disease and who are at increased 
risk for coronary heart disease are likely to be benefitted from hormone therapy.” 
Any advantage of oestrogen in cardiovascular disease and prevention of bone 
loss must be weighed against the risk of developing uterine cancer and breast cancer 
with long time use.  
Cardiovascular benefit of oestrogen is due to its effect on lipoprotein levels, 
oxidation of low density lipoproteins, coagulation and vasomotor function. 
There was a significant decrease in cardiovascular risk in women on oestrogen 
therapy who had no increased cholesterol level as per the Nurses’ health study. 
The alteration in the level of lipoprotein in hypercholesterolemic women can be 
achieved with oestrogen administration. For mildly hypercholesterolemic 
postmenopausal women, lipid lowering therapy is proved to be useful. According to 
the guidelines of National Cholesterol Education Programme II, it is desirable to 
reduce the level of low density lipoproteins to less than 100 mg/dl. 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
PLACE OF STUDY 
 Study was conducted in the Department of Medicine, Government Rajaji 
Hospital, Madurai in co-ordination with the Institute of Physiology, Madurai Medical 
College for a period of one year. 
COLLABORATION DEPARTMENT 
 Department of Biochemistry, Madurai Medical College, Madurai.  
ETHICAL COMMITTEE 
 Approval obtained from the ethical committee of Government Rajaji Hospital, 
Madurai. 
STUDY DESIGN 
 Prospective cross sectional study 
SAMPLE SIZE 
 Total subjects   - 90 
STUDY POPULATION 
Postmenopausal women attending the outpatient department of medicine, 
Government Rajaji Hospital / Madurai Medical College for master health check up. 
 
 
Inclusion Criteria: 
1. Age between 45 - 60 years 
2. Attained natural menopause 
3. Not on Hormone Replacement Therapy 
Exclusion criteria: 
1. Known congenital and acquired heart diseases 
2. Systemic diseases - Hypertension, Diabetes mellitus, Hepatic and Metabolic 
 diseases 
3. Chronic drug intake like Rifampicin, Phenytoin, Anticoagulants, Statins etc 
4. Thyroid dysfunction 
5. Smoking 
MATERIALS USED FOR STUDY 
1. Proforma – to record the anthropometric measurements and the clinical 
findings of the subjects. 
2. Portable weighing machine – to record the body weight in kilograms. 
3. Stadiometer – to measure the standing height in centimeters. 
4. Standardized mercury sphygmomanometer – to record the blood pressure in 
mm of Hg. 
 
 
 METHODOLOGY: 
The study was initiated with the approval of Institutional ethical committee, 
Madurai Medical College, Madurai and was carried out after explaining the 
procedures in detail and getting written informed consent from the subjects.  
The experimental protocol includes 
1) Recording of a detailed history including type (natural/surgical) and duration of 
menopause, history of cardiovascular disease, diabetes mellitus, hypertension, surgery 
or any drug intake and history of endocrine disorders. 
2) General and systemic examination done and the subjects who are eligible for the 
study are selected. 
3) Dividing into three groups  
90 postmenopausal women are selected and are divided into three groups with 30 in 
each group based on the duration of menopause. 
 First group - Thirty postmenopausal women whose duration of menopause is below 5 
years. 
 Second group-Thirty postmenopausal women whose duration of menopause is in 
between 5 years and 10 years. 
 Third group -Thirty postmenopausal women whose duration of menopause is above 
10 years. 
 
 
4) Measurement  of  Anthropometric Indices:   
The subjects are asked to stand erect with their arms relaxed at their side and feet 
together. 
 The following are measured: 
 Weight (in kilograms) is recorded using a portable standard weighing machine. 
 Height (in centimeters) is recorded using a stadiometer.  
 Body Mass Index is found out using Quetelet’s Index.                
Body Mass Index = Weight (Kg)/ Height (sq.m). 
1. Recording of vital signs viz. pulse rate, respiratory rate and measurement of blood 
pressure are done and documented. 
2. Blood investigations:  The investigations include 
1. Serum oestradiol 
2. Lipid profile includes parameters like Total cholesterol, Triglycerides, High density 
lipoproteins, Low density lipoproteins and Very low density lipoproteins. 
After 10-12 hours of fasting, skin is sterilized with a spirit cotton swab and 
blood sample is collected from antecubital vein of front of forearm. About 3ml of 
blood is collected in a disposable syringe of 5ml capacity. For separation of serum, 
blood taken in a glass tube is first allowed to clot at room temperature and then 
centrifuged. This separated serum is used to estimate serum oestradiol and lipid 
profile. 
 
 
ESTIMATION OF OESTRADIOL: 
Method:  
Quantitative determination of serum oestradiol is done by Chemiluminescence 
immunoassay method (CLIA). 
Principle: 
Luminescent immunoassays differ from the ELISA technique in which 
conversion to the product emitting photons of light takes place as an alternative to 
develop a noticeable colour.  
This emission of photons is detected by a luminescent signal instrument. The 
radiant effect is evaluated in relative light units (RLU) which is in proportion to the 
quantity of the substance to be analysed in the test sample. 
The essential ingredients needed for this assay include native antigen, 
biotinylated antibody, enzyme conjugate and signal reagent, the luminol. 
Procedure: 
 13µl of samples and controls are added into the appropriate wells of microplate 
coated with streptavidin.   
 25µl of Biotin reagent is added into each well of microplate luminometer. 
 Using orbital shaker the plate is swirled for 1minute and then incubated for 30 
minutes at room temperature. 
 
 25µl of Tracer reagent- Horse Radish Peroxidase enzyme conjugate is added 
directly on top of the reagent dispensed in the wells and mixing is done by swirling 
the plate for 1 minute followed by incubation for 60 minutes at room temperature. 
 Plate is washed 5 times with 350µl of wash buffer and then 50µl of signal reagent, 
the Luminol chemiluminescent substrate is added into the microwells and 
incubated at room temperature for 5 minutes. 
 Relative luminosity values (RLU) are scanned by photon counter reader. 
Reference range: 
          Phase of menstrual cycle  Range 
            Follicular Phase 9 – 175 pg/ml 
            Luteal Phase 44 – 196 pg/ml 
       Postmenopausal phase 10 – 40 pg/ml 
 
The comparison of the serum oestradiol level between the three groups of 
postmenopausal women is done. 
 
 
 
 
 
 
 
ESTIMATION OF LIPID PROFILE 
               In this study, we measure serum levels of lipid profile comprising of total 
cholesterol, triglycerides, high density lipoproteins, low density lipoproteins and very 
low density lipoproteins. 
A lipid profile typically includes: 
 Total cholesterol (TC) - In this we measure all of the cholesterol content present in 
all the lipoprotein particles by Cholesterol oxidase - Peroxidase enzymatic method. 
 Triglycerides (TGL) - We measure the triglycerides present in all the lipoprotein 
particles by Glycerol kinase - Peroxidase enzymatic method. 
 High density lipoprotein (HDL) - We measure the cholesterol present in high 
density lipoprotein particles by precipitation method. 
 Low density lipoprotein (LDL) - We calculate the cholesterol present in low density 
lipoprotein particles; The amount of low density lipoprotein is calculated by 
Friedewald formula. 
          LDL = total cholesterol - (high density lipoprotein+ triglycerides/5) 
 Very low density lipoprotein (VLDL) - We calculate from level of triglycerides. 
          Very low density lipoprotein = triglycerides/5. 
 
 
Reference range: 
TYPES FAVOURABLE BORDERLINE RISK 
Total cholesterol 
(mg/dl) 
Below 200 200-239 240 
Triglycerides 
(mg/dl) 
Below 150 150-199 200-499 
High density 
lipoprotein (mg/dl) 
60 50-59 <50 
Low density 
lipoprotein (mg/dl) 
60-130 130-159 160-189 
Very low density 
lipoprotein (mg/dl) 
2-30 30-40 40-100 
 
Lipid profile values are compared between the three groups and correlation of 
serum oestradiol level with lipid profile is done. 
 
 
 
 
 
 
RESULTS AND OBSERVATION 
The comparison of oestradiol levels and lipid profile values between the three 
groups is done and the results are analysed using ANOVA calculations.  
The correlation of serum oestradiol level with body mass index and lipid 
profile which includes total cholesterol, high density lipoprotein, low density 
lipoprotein, very low density lipoprotein and triglycerides is done by Pearson’s 
correlation. 
By means of SPSS software version 16, analysis of statistics is performed. 
The ‘p’ value < 0.05 is considered as significant statistically. 
 
 
 
 
 
 
 
 
 
Table: 1 
Mean values of various parameters 
 
PARAMETERS 
 
 
 
GROUP 
I 
(mean) 
 
 
GROUP 
I 
(SD) 
 
 
GROUP 
II 
(mean) 
 
 
 
GROUP 
II 
(SD) 
 
 
GROUP 
III 
(mean) 
 
 
GROUP 
III 
(SD) 
 
 
‘p’ 
value 
 
AGE ( years) 
 
 
46.73 
 
2.227 
 
52.67 
 
2.202 
 
57.53 
 
2.030 
 
.000 
 
DURATION OF 
MENOPAUSE  
(years) 
 
3.200 
 
0.714 
 
7.800 
 
1.095 
 
12.60 
 
1.354 
 
.000 
 
HEIGHT 
(centimetres) 
 
152.43 
 
7.718 
 
155.70 
 
7.489 
 
151.10 
 
5.448 
 
.036 
 
WEIGHT 
(kilograms) 
 
55.83 
 
11.354 
 
63.90 
 
10.233 
 
64.90 
 
8.314 
 
.001 
 
BODY MASS 
INDEX 
(kg/sq.m) 
 
 
23.96 
 
4.101 
 
26.36 
 
3.852 
 
28.46 
 
3.521 
 
.000 
 
 
 Table : 2 
Comparison of serum oestradiol levels between three groups 
Duration               
of menopause 
Groups Oestradiol (pg/ml) ‘p’ value 
Mean Standard 
deviation 
Less than 5 years Group I 46.660 12.63  
<0.001 
Significant 
 
5- 10 years Group II 25.400 5.46 
More than               
10 years 
Group III 16.840 6.95 
 
 The serum oestradiol level decreases significantly as the duration of 
menopause increases. 
 
 
 
 
Table : 3 
Comparison of lipid profile values between three groups 
 
PARAMETERS 
 
 
 
 
 
GROUP 
I 
(mean) 
 
GROUP 
I 
(SD) 
 
 
GROUP 
II 
(mean) 
 
 
GROUP 
II 
(SD) 
 
GROUP 
III 
(mean) 
 
GROUP 
III 
(SD) 
 
‘p’ 
value 
 
Total cholesterol 
(mg/dl) 
 
164.88 
 
24.289 
 
180.95 
 
26.619 
 
184.04 
 
22.010 
 
.006 
High density  
lipoprotein 
(mg/dl) 
 
44.53 
 
7.860 
 
35.00 
 
4.331 
 
32.77 
 
4.606 
 
.000 
Low density  
lipoprotein 
(mg/dl) 
 
94.72 
 
22.437 
 
122.54 
 
28.739 
 
127.71 
 
23.430 
 
.000 
Very low density  
lipoprotein 
 (mg/dl) 
 
24.85 
 
5.421 
 
25.95 
 
6.635 
 
23.51 
 
7.590 
 
.365 
Triglycerides 
(mg/dl) 
 
123.47 
 
28.084 
 
128.08 
 
33.874 
 
129.95 
 
32.083 
 
.714 
While comparing the mean values of lipid profile between the three groups, 
total cholesterol and low density lipoprotein levels are increased significantly. Level 
of triglycerides is increased but it is insignificant. There is a significant decrease in 
high density lipoprotein level.  
 Table : 4 
Correlation of oestradiol level with body mass index 
GROUPS OESTRADIOL 
(pg/ml) 
BODY MASS 
INDEX 
(kg/sq.m) 
CORRELATION 
COEFFICIENT 
 Group I 46.660 23.96 -0.180 
 Group II 25.400 26.09 -0.174 
 Group III 16.840 28.46 -0.368 
 
As the duration of menopause increases, the serum oestradiol level decreases 
with the increase in body mass index. So theserum oestradiol level is negatively 
correlated with body mass index. 
 
 
 
 
 
 Table : 5 
Correlation of oestradiol level with total cholesterol 
GROUPS OESTRADIOL 
(pg/ml) 
TOTAL 
CHOLESTEROL 
(mg/dl) 
CORRELATION 
COEFFICIENT 
 Group I 46.660 164.87 -0.098 
Group II 25.400 180.95 -0.220 
Group III 16.840 184.04 -0.070 
 
As the duration of menopause increases, the serum oestradiol level decreases 
with the increase intotal cholesterol. So the serum oestradiol level is negatively 
correlated with the level of total cholesterol. 
 
 
 
 
 
Table : 6 
Correlation of oestradiol level with high density lipoprotein 
GROUPS OESTRADIOL 
(pg/ml) 
HIGH                  
DENSITY 
LIPOPROTEIN 
(mg/dl) 
CORRELATION 
COEFFICIENT 
Group I 46.660 44.53 0.240 
Group II 25.400 35 0.330 
Group III 16.840 32.77 0.270 
 
As the duration of menopause increases, the serum oestradiol level decreases 
with the decrease in high density lipoprotein. So the serum oestradiol level is 
positively correlated with the level of high density lipoprotein. 
 
 
 
 
 
 
Table : 7 
Correlation of oestradiol level with low density lipoprotein 
GROUPS OESTRADIOL 
(pg/ml) 
LOW        
DENSITY 
LIPOPROTEIN 
(mg/dl) 
CORRELATION 
COEFFICIENT 
 GROUP I 46.660 94.72 -0.097 
 GROUP II 25.400 122.54 -0.200 
 GROUP III 16.840 127.71 -0.070 
 
As the duration of menopause increases, the serum oestradiol level decreases 
with the increase in low density lipoprotein. So the serum oestradiol level is 
negatively correlated with the level of low density lipoprotein. 
 
 
 
 
 
 
Table : 8 
Correlation of oestradiol level with very low density lipoprotein 
GROUPS OESTRADIOL 
(pg/ml) 
VERY                    
LOW        
DENSITY 
LIPOPROTEIN 
(mg/dl) 
CORRELATION 
COEFFICIENT 
GROUP I 46.660 24.85 -0.060 
GROUP II 25.400 25.95 -0.060 
GROUP III 16.840 23.51 -0.200 
 
As the duration of menopause increases, the serum oestradiol level decreases 
without any significant change in the level of very low density lipoprotein. 
 
 
 
 
 
 
Table : 9 
Correlation of oestradiol level with triglycerides 
GROUPS OESTRADIOL 
(pg/ml) 
TRIGLYCERIDES 
(mg/dl) 
CORRELATION 
COEFFICIENT 
GROUP I 46.660 123.47 -0.070 
GROUP II 25.400 128.08 -0.110 
GROUP III 16.840 129.95 -0.140 
 
As the duration of menopause increases, the serum oestradiol level decreases 
with the increase in triglycerides. So the serum oestradiol level is negatively 
correlated with the level of triglycerides. 
 
 
 
 
 
 
Table : 10 
Correlation of serum oestradiol with body mass index and lipid profile in              
Group I 
 
 
 
 
 
 
 
 
Group I   (less than 5 
years) 
Correlation 
coefficient 
  
Oestradiol with BMI -0.180 Negative correlation 
Oestradiol with TC -0.098 Negative correlation 
Oestradiol with  HDL 0.240 Positive correlation 
Oestradiol with LDL -0.097 Negative correlation 
OestradiolwithVLDL -0.060 Negative correlation 
Oestradiol with TGL -0.070 Negative correlation 
Table : 11 
Correlation of serum oestradiol with body mass index and lipid profile in 
Group II 
Group II  (5-10 years) Correlation 
coefficient 
 
Oestradiol with BMI -0.174 Negative correlation 
Oestradiol with TC -0.220 Negative correlation 
Oestradiol with  HDL 0.330 Positive correlation 
Oestradiol  with LDL -0.200 Negative correlation 
Oestradiol  with VLDL -0.060 Negative correlation 
Oestradiol with TGL -0.110 Negative correlation 
 
 
 
 
 
 
 Table : 12 
Correlation of serum oestradiol with body mass index and lipid profile in 
Group III 
Group III 
( more than 10 years) 
Correlation 
coefficient 
  
Oestradiol with BMI -0.368 Negative correlation 
Oestradiol with TC -0.070 Negative correlation 
Oestradiol with  HDL 0.270 Positive correlation 
Oestradiol  with LDL -0.070 Negative correlation 
Oestradiol  with VLDL -0.200 Negative correlation 
Oestradiol with TGL -0.140 Negative correlation 
 
 
 
 
 
 From Pearson’s correlation it is found that there exists negative correlation 
between serum oestradiol level and the values of  
 Body mass index 
 Total cholesterol 
 Low density lipoprotein 
 Very low density lipoprotein 
 Triglycerides 
There is a positive correlation of serum oestradiol level with high density 
lipoprotein. 
 
 
 
 
 
 
 
 
 
 
 
 
 DISCUSSION 
The term “menopause” literally means the last menstrual period and 
postmenopause is the time that follows menopause. Menopause usually occurs                                          
in between the age of 45 and 55 years. 
In our present study, we have divided the postmenopausal women into three 
groups based on the duration of menopause. The mean age of postmenopausal women 
in group I is 46.73 ± 2.23 years, group II is 52.67 ± 2.20 years and group III is 57.53 ± 
2.03 years. The mean duration of menopause in group I is 3.2 ± 0.71 years, group II 
is7.8 ± 1.09 years and group III is 12.6 ± 1.35 years. 
Every woman has to undergo a normal physiological event in her life called 
menopause and it is due to changes in level of hormones which results from the loss 
of ovarian function. But a large amount of androgen is secreted from ovarian stroma 
and adrenal cortex in postmenopausal women which is converted to oestrogen in 
peripheral tissues. This quantity of oestrogen is very minimal as compared with the 
premenopausal state. 
The postmenopausal period is a state of oestrogen deficiency. Lack of 
oestrogen causes unfavourable changes in the metabolism of glucose and insulin, 
blood coagulation, fat distribution in the body, fibrinolytic system, endothelial 
function of the blood vessels and alteration in the lipid profile (Bales AC et al., 2000, 
S A Samaan et al., 1995). It is essential to draw more of our attention to alleviate and 
understand the long term results of deficiency of the hormone oestrogen. 
The mean value of serum oestradiol in group I is 46.660 ± 12.63 pg/ml, group 
II is 25.400 ± 5.464 pg/ml and group III is 16.840 ± 6.95 pg/ml. The level of 
oestradiol decreases significantly (p < 0.001) with increase in the duration of 
menopause.  
Serum lipid levels vary in every individuals and they depend on body mass 
index, level of exercise, history of smoking, dietary habits, systemic diseases like 
hypertension, diabetes mellitus, liver and metabolic diseases (Gordon T et al., 1981). 
So in our study, we excluded these confounding variables. 
In our study, mean value of body mass index in group I is 23.96 ± 4.10 
kg/sq.m, group II is 26.36 ± 3.85 kg/sq.m and group III is 28.46 ± 3.52 kg/sq.m. The 
level of body mass index increases significantly (p < 0.001) with increase in the 
duration of menopause. 
Blumel J E et al., 2001 studied on premenopausal women. He reevaluated 
after five years and found a similar weight gain present in women who attained 
menopause and those who did not attain menopause. According to Akahoshi et al., 
1996 body mass index is related to menopausal age and later the menopausal age, 
greater will be the body mass index. In studies of Razay et al., 1992 and Akahoshi et 
al., 1996, it is shown that body mass index increases in postmenopausal period.  
As suggested by Jousilahti et al., 1996 factors determining body weight are 
physical activity, genetic and cultural factors, socioeconomic status, psychological 
factors etc.  
Some other researchers suggest that any decrease in the level of basal 
metabolism and reduction of physical activity may increase the body weight in 
postmenopausal women. 
Poehlman et al., 1995 stated that oestrogen deficiency after menopause is 
linked with an increased body mass in women. Oestrogen  potentiate the secretion of 
growth hormone and if this potentiation is lost after menopause. Body weight 
increases due to the loss of this trophic effect on skeletal muscle growth 
Oestrogen can modulate the cytokines activity which leads on to the catabolic 
milieu. For example the interleukin-6 production is prevented by oestradiol and 
oestrogen deficiency could cause an increased interleukin-6 activity. This results in 
catabolic effects 
Dr. Maulik S. Varu et al., in 2011 compared the serum lipid profile between 
premenopausal and postmenopausal women. He concluded that the mean level of total 
cholesterol and low density lipoprotein were significantly elevated in postmenopausal 
women as compared with premenopausal women. Significant increase is seen when 
the duration of menopause is increased. The high density lipoprotein level was 
significantly decreased in postmenopausal women and it is decreased significantly 
when the duration of menopause is increased. The limitation of that study was failure 
of measuring the oestradiol level which could be the cause for lipid profile 
derangement in postmenopausal women and it is rectified in our present study. Here 
serum oestradiol level is measured and it is correlated with changes in the lipid profile 
in postmenopausal women of various duration of menopause. 
Similar comparative studies of serum lipid profile between premenopausal and 
postmenopausal women were done by HA Eltayeb et al., 2015, Dr.M.Swarnalatha 
et al., 2015, Gulab Kanwaret al., 2014 and Rajesh K Jambhulkar et al., 2014. 
Over all conclusion discussed in above studies is in postmenopausal women, 
mean values of total cholesterol and low density lipoprotein were significantly 
increased as compared with premenopausal women. While the high density 
lipoprotein level was significantly lower in postmenopausal women. 
A correlative study with oestrogen and lipid profile in premenopausal and 
postmenopausal women was done by Swarnalatha P K et al., 2012 in which she 
studied the influence of oestrogen on the levels of total cholesterol, high density 
lipoprotein, low density lipoprotein, triglycerides, very low density lipoprotein and 
ratio between total cholesterol and high density lipoprotein. The correlation of 
oestrogen level with high density lipoprotein was decreased significantly in 
postmenopausal women whose duration of menopause is more than ten years but no 
significant correlation was noted in postmenopausal women whose duration of 
menopause is less than ten years. 
In our present study, in postmenopausal women as the duration of menopause 
increases, the changes in lipid profile values are noted and are correlated with serum 
oestradiol level. 
While comparing the mean values of lipid profile between the three groups, 
total cholesterol (p=0.006) and low density lipoprotein (p<0.001) levels are increased 
significantly. Level of very low density lipoprotein (p=0.365) and triglycerides 
(p=0.714) are increased but insignificant. There is a significant decrease in high 
density lipoprotein (p<0.001) level. 
 
OESTRADIOL WITH TOTAL CHOLESTEROL  
In our study the mean value of total cholesterol in group I is 164.88 ± 24.29 
mg/dl, group II is 180.95 ± 26.62 mg/dl and group III is 184.04 ± 22.01 mg/dl. This 
shows significant increase as the duration of menopause increases. In our present 
study level of oestrogen is negatively correlated with total cholesterol values 
(correlation coefficient in group I is -0.098, in group II it is -0.220 and in group III it 
is -0.070). 
Niklila et al stated that ethinyloestradiol increases the turnover of cholesterol. 
Edward et al suggested that even though it appears that the cholesterol synthesis is 
increased by oestrogen actually the excretion rate is increased which results in the 
decline of serum cholesterol level.  
Total levels of high density lipoprotein, low density lipoprotein and very low 
density lipoprotein constitute the total cholesterol. During postmenopausal period the 
level of low density lipoprotein and very low density lipoprotein are increased but the 
level of high density lipoprotein is decreased. The elevation of low density lipoprotein 
and very low density lipoprotein level is more than the reduction in high density 
lipoprotein level. This results in net elevation of total cholesterol level after 
menopause.  
 
 
 
OESTRADIOL WITH HIGH-DENSITY LIPOPROTEIN 
According to the report of Do KA et al., 2000, in postmenopausal women the 
rate of reduction in the level of high density lipoprotein was maximum at about nine 
months after menopause and the rate was calculated to be around 21.26 mg/dl per 
year.  
In our study the mean value of high density lipoprotein cholesterol in group I is 
44.53 ± 7.86 mg/dl, group II is 35 ± 4.33 mg/dl and group III is 32.77 ± 4.61 mg/dl. 
This shows significant decrease as the duration of menopause increases. Oestrogen 
levels are positively correlated with the level of high density lipoprotein (the 
correlation coefficient in group I is 0.240, in group II it is 0.330 and in group III it is 
0.270). 
Kalavathi et al., in1991 stated that oestrogen act on the enzyme hepatic lipase 
which is otherwise called Heparin Releasable Hepatic lipase (HRHL). This enzyme is 
present in the endothelial cells of liver and it catalyzes the high density lipoproteins. 
The enzyme hepatic lipase is preferably attached with HDL2 than with HDL3 
and low density lipoprotein. Hepatic lipase is therefore called HDL2 phospholipase 
and it increases the cholesterol uptake by liver. It also helps to convert the HDL2 to 
HDL3. Only in the form of HDL3, cholesterol is accepted from peripheral tissues. 
After the conversion of HDL3 to HDL2 it is taken up by liver. Oestrogen reduces the 
activity of hepatic lipase and thereby HDL2 level in plasma is increased. 
The main action of high density lipoprotein is the esterification and exchange 
of cholesterol. The mobilisation of cholesterol from the body tissues and 
transportation to liver is done by high density lipoprotein so that they subsequently 
undergo catabolism and are excreted (Siteri P.K. et al., 1988). 
 In studies of Miller CJ et al., 1975, the plasma cholesterol level has negative 
correlation with high density lipoprotein concentration. The transport of cholesterol 
from arterial wall to liver by high density lipoproteins reduces the development of 
atherosclerosis. 
The enzyme lecithin cholesterol acyl transferase causes the esterification of 
cholesterol using high density lipoproteins as a substrate. The cholesterol esters are 
taken back to liver in the form of low density lipoproteins and very low density 
lipoproteins. In liver, the lipoproteins are degraded and hydrolysis of cholesterol esters 
takes place (Sharma V.N. et al., 1998). 
In 2000, Edmunds and Lip suggested that the hepatic lipase which normally 
catalyzes thehigh density lipoprotein is inhibited by oestrogen. So in postmenopausal 
period the inhibition by oestrogen disappears and more of high density lipoproteins 
are destroyed by hepatic lipase. This results in decrease in the level of high density 
lipoproteins in women after menopause. 
This high density lipoprotein also inhibits the process of uptake of low density 
lipoprotein which is rich in cholesterol by the smooth muscle cells of arteries. When 
the high density lipoprotein is decreased, accumulation of more amount of cholesterol 
in arteries results. This promotes the occurance of atherosclerosis due to lack of 
proper clearance of cholesterol. 
Oestrogen replacement therapy increases the level of high density lipoproteins 
(Vasudevan DM et al., 2001; Tapiero H et al., 2002). Oestrogen also increases the 
receptors for high density lipoproteins in liver. 
As per the study of Allaupovic et al, oestrogen specifically increases the 
production of high density lipoproteins in liver.  
 
OESTRADIOL WITH LOW - DENSITY LIPOPROTEIN 
In our study the mean value of low density lipoprotein cholesterol in group I is 
94.72 ± 22.44 mg/dl, group II is 122.54 ± 28.74 mg/dl and group III is 127.71 ± 23.43 
mg/dl. This shows significant increase as the duration of menopause increases. 
Oestrogen level shows a negative correlation with low density lipoprotein cholesterol 
(the correlation coefficient in group I is -0.097, in group II it is -0.220 and in group III 
it is -0.070). 
Wakatsuki et al., in 1998 stated that a reduction in the concentration of 
oestrogen in postmenopausal period increases the activity of lipoprotein lipase and 
that leads to an elevation in the concentration of low density lipoproteins.  
According to Arca et al., 1994, the hypercholesterolemia in women after 
menopause is mainly due to defect in low density lipoprotein receptors. In 
premenopausal period, oestrogen induces the production of low density lipoprotein 
receptors on hepatic surface that increases the clearance of low density lipoproteins 
resulting in decreased plasma level. 
In the studies of Abraham and Villablanca et al., 2002, it is suggested that 
decrease in the level of low density lipoproteins after oestrogen therapy is due to 
increased uptake of lipoproteins by liver, conversion of more of cholesterol into bile 
acids in liver and accelerated low density lipoprotein receptor expression on 
hepatocytes. This increases the clearance of low density lipoprotein particles from 
plasma.  
They also suggest that the foam cell formation is an essential step in process of 
atherosclerosis which is due to the LDL oxidation and phagocytosis by macrophages. 
 
OESTRADIOL WITH VERY LOW DENSITY LIPOPROTEIN 
According to our study, mean value of very low density lipoprotein cholesterol 
in group I is 24.85 ± 5.42 mg/dl, group II is 25.95 ± 6.64 mg/dl and group III is 23.51 
± 7.59 mg/dl. This shows an increase in very low density lipoprotein level as the 
duration of menopause increases but it is insignificant. Oestrogen shows a negative 
correlation with very low density lipoprotein cholesterol (the correlation coefficient in 
group I is -0.060, in group II it is -0.060 and in group III it is -0.200). 
The level of very low density lipoproteins may increase after menopause. As 
per the study of Wakatsuki et al., 1998, low density lipoprotein is formed from very 
low density lipoprotein in liver. An elevation in very low density lipoprotein secretion 
is mainly due to an increased activity of post heparin plasma lipoprotein lipase. 
 
 
 
 
 
OESTRADIOL WITH TRIGLYCERIDES 
As per our study, mean value of triglycerides in group I is 123.47 ± 28.08 
mg/dl, group II is 128.08 ± 33.87 mg/dl and in group III is 129.95 ± 32.08 mg/dl. This 
shows an increase in triglycerides level as the duration of menopause increases but it 
is insignificant. Oestrogen level shows a negative correlation with triglycerides (the 
correlation coefficient in group I is -0.070, in group II it is -0.110 and in group III it is 
-0.140). 
In women after menopause, the plasma levels of both oestrogen and 
progesterone decreases. Because of oestrogen deficiency, adipocyte size increases and 
there is an increased activity of lipoprotein lipase. This results in the release of 
triglycerides from adipocytes. The reduced level of progesterone also causes hepatic 
release of triglycerides. Ultimately the level of triglycerides increases in 
postmenopausal women. 
According to Pradhan P et al., 2013 in postmenopausal women, the major 
modifiable risk factors for coronary heart disease are  
 Hypertension 53.8% 
 Smoking 35.0% 
 Diabetes mellitus 23.03% 
 Hyperlipidemia 8.1% 
In modern society, the coronary heart disease is one of the major etiology for 
morbidity in women after menopause. In females after menopause, the values of lipids 
and lipoproteins are changed towards increased atherogenicity (e.g. rise in low density 
lipoprotein and fall in high density lipoprotein levels). These changes result in 
increased incidence of cardiovascular disease in postmenopausal women. 
American Heart Association report in 2002, stated that 70% of women after 
menopause develop cardiovascular disease. Increased risk seen in postmenopausal 
women may be due to decrease in the favourable effects of oestrogen on blood vessels 
and lipid profile (Marynard C et al., 1992). According to Bush et al., 1988, in 
females the levels of lipids and lipoproteins are determined by female sex hormones. 
Stevenson et al., in 1993 suggested that after menopause, adverse changes are 
seen in lipid and lipoprotein levels and are not due to the effect of ageing. This is due 
to the loss of endogenous oestrogen and its protective effects. 
As per the study of Kannel WB et al., 1995, elevated plasma levels of low 
density lipoprotein and total cholesterol are the major risk factors for the development 
of cardiovascular disease. 
A 10% reduction in cholesterol level may decrease the risk of cardiovascular 
disease by 10% in less than 4 years (Pharoah PD et al., 1996). Level of high density 
lipoprotein in contrast to those of low density lipoprotein and total cholesterol are 
inversely related to the risk of coronary heart disease (Miller NE et al., 1977). 
 
 
 
 
 
 
CONCLUSION 
Menopause is the physiological process of ageing in which the general health 
of women is altered. The long term deficiency of oestrogen with increase in the 
duration of menopause decreases the protection from coronary heart disease by 
altering the lipid levels. 
The lipid profile values are unfavourable in postmenopausal women with 
longer duration of menopause and it is considered as a strong predictor for 
cardiovascular disease. Therefore, screening of every postmenopausal woman for 
abnormal lipid profile is mandatory. 
In postmenopausal women health strategies in the form of dietary interventions 
and increased physical activity are need to be encouraged. Lipid lowering drugs are 
proved to be useful. Hormone replacement therapy in postmenopausal women is 
likely to protect against cardiovascular disease through its action on lipid levels.  
 To conclude it is important to monitor the lipid profile of postmenopausal 
women regularly and to give proper guidance regarding diet and physical activities so 
that the population of older women can be expected to increase in the coming decades 
without any risk to their general health. 
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ABBREVIATIONS 
 
GnRH    Gonadotrophin releasing hormone 
FSH                            Follicle stimulating hormone 
LH                             Luteinizing hormone 
BMI                            Body mass index 
TC                              Total cholesterol 
HDL                           High density lipoprotein 
LDL                             Low density lipoprotein 
VLDL                         Very low density lipoprotein 
TGL                            Triglycerides 
HPO axis                   Hypothalamo-Pituitary-Ovarian axis 
 
 
 
 
 
 
 
PROFORMA 
Name:                                         Age:                            Address: 
HISTORY: 
PRESENT HISTORY 
H/o palpitation                                                                                                               
H/o difficulty in breathing                                                                                                        
H/o syncope                                                                                                                        
H/o weight gain                                                                                                            
PAST HISTORY 
H/o Hypertension                                                                                                               
H/o Diabetes                                                                                                                             
H/o Heart diseases                                                                                                                                   
H/o Thyroid disorders 
PERSONAL HISTORY 
H/o Drug intake                                                                                                                                          
H/o Smoking   
DIET HISTORY                                 Vegetarian/Non vegetarian                                                                                                                                                                                                                       
MENSTRUAL HISTORY 
Type of Menopause - Natural/Surgical                                                                      
Duration of Menopause - Less than 5 years/5-10 years/More than 10 years 
GENERAL EXAMINATION: 
Comfortable at rest                                                                                                                 
Pallor                                                                                                                                  
Cyanosis                                                                                                             
Clubbing                                                                                                                        
Jaundice                                                                                                                               
Pedal edema                                                                                                                   
Height (cm):                      Weight (kg):                    BMI (Kg/sq.m):            
Pulse rate (per min):              JVP:                             BP (mm of  Hg):  
 
 
SYSTEMIC EXAMINATION: 
CARDIOVASCULAR SYSTEM 
 
RESPIRATORY SYSTEM 
 
ABDOMEN 
 
CENTRAL NERVOUS SYSTEM 
 
 
 INVESTIGATIONS: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Cholesterol 
(mg/dl) 
 
 
High Density Lipoprotein 
(mg/dl) 
 
 
Low  Density Lipoprotein      
(mg/dl) 
 
 
Very Low Density Lipoprotein 
(mg/dl) 
 
 
Triglycerides (mg/dl) 
 
 
Serum Oestradiol                             
(pg/ml) 
 
 
Nehahsp jfty; kw;Wk; xg;Gjy; gbtk; 
,izg;G – 3 
Ma;tplj; jfty; kw;Wk; njhlHG tptuq;fs; 
 khjtplhnahopT ele;j ngz;fSf;F nfhOkpa tpyf;fzr;Nrhjid 
KbT kw;Wk; CePhpd; <];l;uilahy; msT gw;wp Mha;jy; 
 ,e;jg; gf;fj;ij ifnahg;gkpLtjd; %ykhf> gpd;tUtdtw;iw ehd; 
cWjp nra;fpNwd;. 
 Nkw;gb Ma;tpw;fhd [dthp 2015 Njjpaplg;gl;l ,e;j Nehahspj; jfty; 
kw;Wk; xg;Gjy; gbtj;jpYs;s midj;Jj; jfty;fisAk; ehd; gbj;Jg; 
ghpe;J nfhz;bUf;fpNwd; vdTk;> mijg; gw;wp rpe;jpf;f vdf;F fhy 
mtfhrk; ,Ue;jJ vdTk; ehd; cWjpaspf;fpNwd;. 
 Nfs;tpfs; Nfl;gjw;fhd tha;g;G vdf;F ,Ue;jJ. NkYk; vdJ 
Nfs;tpfs; midj;Jk; vdJ jpUg;jpf;Fj; jf;fthW 
gjpyspf;fg;gl;bUf;fpd;wd. 
 ,e;j Ma;tpy; vd; Foe;ijapd; gq;Nfw;G vd; jd;dhHtk; rhHe;jJ 
vdTk;> gq;Nfw;ig vg;NghJ Ntz;LkhdhYk; vt;tpjf; fhuzKk; 
mspf;fhky;> vd; Foe;ijapd; kUj;J ftdpg;G my;yJ rl;l chpikfs; 
ghjpf;fg;glhky; tpyf;fpf; nfhs;s ehd; Rje;jpukhdtH vd;gij ehd; 
Ghpe;J nfhs;fpNwd;. 
 Ntz;bf; nfhs;sg;gl;lg;gb> Ma;T eilKiwfis gpd;gw;wTk;> kw;Wk; 
kUj;JtH> nrtpypfs;> my;yJ kw;w Copa cWg;gpdHfSf;F Njitahd 
jfty;fis toq;fTk; ehd; jd;dhHtj;Jld; xg;Gf; nfhs;fpNwd;. 
 kUj;Jt Nrhjidapd; epjpAjtpaspf;Fk; epWtdk;> epjpAjtpaspf;Fk; 
epWtdj;jpd; rhHgpy; gzpahw;Wk; kw;wtHfs;> ed;ndwpfs; FO kw;Wk; 
xOq;F Kiw mjpfhhpfs; MfpNahUf;F> jw;Nghija Ma;T 
rk;ge;jkhfTk; juT ghJfhg;G mwpf;ifapy; Fwpg;gpl;lg;gbAk;> vdJ 
Foe;ijapd; MNuhf;fpag; gjpNtLfisg; ghHitapLtjw;F vdJ mDkjp 
Njitg;glhJ vd;gij ehd; Ghpe;J nfhs;fpNwd;. ,e;j mZfYf;F ehd; 
xg;Gf; nfhs;fpNwd;. ,Ue;jhYk;> %d;whk; egHfSf;F ntspaplg;gLk; 
my;yJ gpuRhpf;fg;glk; ve;jnthU jfty;fspYk; vdJ Foe;ijapd; 
milahskhdJ ntspg;gLj;jg;glhJ vd;gij ehd; Ghpe;J nfhs;fpNwd;. 
 ,e;j Ma;tpypUe;J vOk; ve;jnthU juT my;yJ KbTfspd; 
cgNahfj;jpidAk;> ,J Nghd;w cgNahfkhdJ juT ghJfhg;G 
mwpf;ifapy; Fwpg;gpl;lg;gb kl;Lkhf cgNahfpf;fg;gLk; gl;rj;jpy; 
mitfisj; jLf;fhkypUf;f ehd; xg;Gf; nfhs;fpNwd;. 
Nkw;fz;l Ma;tpy; vd; Foe;ij gq;nfLf;f ehd; xg;Gf; nfhs;fpNwd;. 
 vdf;fhf itj;Jf; nfhs;tjw;fhf ,e;j Nehahsp jfty; kw;Wk; xg;Gjy; 
gbtj;jpd; xH efiy ehd; ngw;Wf; nfhz;bUf;fpNwd;. 
 
 
Nehahspapd; ifnahg;gk;:    Njjp: 
(my;yJ ngUtpuy; Nuif) 
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Sl.no NAME 
 
AGE 
(years) 
DURATION 
OF 
MENOPAUSE 
(years) 
Ht 
(cm) 
Wt 
(kg) 
BMI 
(kg/sq.m) 
OESTRADIOL 
(pg/ml) 
TC 
(mg/dl) 
HDL 
(mg/dl) 
LDL 
(mg/dl) 
VLDL 
(mg/dl) 
TGL 
(mg/dl) 
1 Selvaboopathi 
 
47                      2      142 56 27.8 30.22 182 57 107 17.3 86.5 
2 Anbumani 
 
48 3                      155 41 17.1 61.3 155 41 94 20 100 
3 Shanthi 48 
 
4 161 58 22.4 39.15 133.3 45 83 25 125 
4 Mariyammal 45 
 
3 149 54 24.3 43.75 237 50 158 29 145 
5 Parameshwari 45 
 
4 138 48 25.2 44 175 37 107 31 155 
6 Palselvi 50 3 152 
 
57 24.7 38.3 162 48 87 27 135 
7 Mariammal 48 
 
2 156 68 27.9 35.26 160 31 66 33 165 
8 Tamilselvi 47 
 
3 150 54 24 42.59 179 46 106 27 135 
9 Rathinammal 46 
 
4 162 75 28.6 57.3 151 56 77.2 17.82 89.1 
10 Sundari 
 
45 4 155 52 21.6 80 138 57 55.1 25.9 129.5 
11 Ranikrishnawathi 
 
45 3 158 60 24 40.46 147 55 71.4 20.6 103 
12 Nagarathinam 
 
45 3 155 65 27.1 48.2 174 52 91 21 105 
13 Rakku 
 
48 4 140 35 17.9 51.6 152 38 92 22 110 
14 Ramalakshmi 
 
45 2 156 56 23 38.3 162 38 99 25 125 
15 Kamatchi 
 
45 4 140 37 18.9 31.4 180 49 109 32 160 
16 Shakthi 
 
44 3 157 57 23.1 39 142 35 84 23 115 
17 Rajeshwari 
 
44 3 140 58 29.6 60.8 167 39 105 23 115 
18 Nagoorammal 
 
47 4 155 52 21.6 78.2 204 45 134 25 125 
19 Valli 
 
49 3 158 60 24 41.4 128 37 69 22 110 
20 Nagarathinam 
 
48 4 147 52 24.1 52.3 161 38 89 34 170 
21 Maruthayee 
 
44 3 156 68 27.9 31.3 184 58 109 37 185 
22 Kavitha 
 
47 2 165 60 22 48 126 40 61 15 58 
23 Angayarkanni 
 
44 4 163 47 17.7 62.1 182 43 108 31 148 
24 Nagalakshmi 
 
51 3 160 94 36.7 54.2 133 40 69 24 120 
25 Petchiammal 
 
45 3 151 46 20.2 46.7 141 46 75 26 130 
26 Anar 
 
51 2 146 57 26.7 30.8 189 42 102 17 85 
27 Bagavathi 
 
44 4 142 51 25.3 44.6 167 32 116 19 95 
28 Muthulakshmi 
 
50 4 147 48 22.2 35.3 175 41 112 22 110 
29 Selvi 
 
50 3 160 61 23.8 42.8 188 43 119 26 130 
30 Shanthi 
 
47 3 157 48 19.5 50.4 172 57 87 28 140 
Sl.no NAME 
 
AGE 
(years) 
DURATION 
OF 
MENOPAUSE 
(years) 
Ht 
(cm) 
Wt 
(kg) 
BMI 
(kg/sq.m) 
OESTRADIOL 
(pg/ml) 
TC 
(mg/dl) 
HDL 
(mg/dl) 
LDL 
(mg/dl) 
VLDL 
(mg/dl) 
TGL 
(mg/dl) 
1 Dhanalakshmi 52 6 153 61 26.1 18.99 201 30 143.7 15.3 76.5 
2 Velthai 
 
50 7 157 72 29.2 27 162 35 198.8 28.2 141 
3 Pitchaiammal 
 
53 10 161 76 29.3 24.73 215.5 31 155.5 19 95 
4 Mariammal 
 
51 8 154 64 27 26.3 209 47 140 22 110 
5 Subbulakshmi 
 
50 9 147 60 27.8 16.15 163 31 147.8 26.2 131 
6 Shanthi 
 
50 9 158 64 25.6 17.35 269 32 192.3 18.7 93.9 
7 Dhanalakshmi 
 
54 8 155 67 27.9 20.98 185 37 124 24 120 
8 Rani 
 
52 7 145 59 28.1 17.2 165 38 96 31 155 
9 Latha 
 
52 7 164 65 24.2 30.6 202 34 133 35 175 
10 Alagu 
 
55 6 153 88 37.6 28.2 172 36 124 12 60 
11 Arulrani 
 
53 7 158 68 27.2 31.3 189 38 134 17 85 
12 Mallika 
 
57 8 150 65 28.9 34.2 171 36 108 27 135 
13 Muthulakshmi 
 
56 9 159 59 23.3 26.8 181 34 125 22 110 
14 Kanagavalli 
 
53 7 153 64 27.3 29.4 144 36 85 23 115 
15 Lakshmi 
 
52 7 151 62 27.2 25.6 148 32 91 25 125 
16 Pitchaiammal 
 
50 8 162 75 28.6 31.7 144 30 86 28 140 
17 Chandra 
 
53 9 156 68 27.9 26.9 169 41 99 29 145 
18 Sathyavanimuthu 
 
54 10 147 58 26.8 24.3 177 34 111 32 160 
19 Indhumathi 
 
55 8 153 50 21.4 20.6 169 31 98 34 170 
20 Seribabeevi 
 
54 7 153 66 28.2 27.4 178 29 112 37 185 
21 Noorjahan 
 
54 9 144 57 27.5 28.1 186 41 130 15 75 
22 Savithri 
 
55 6 158 70 28 31.4 159 33 98 28 90 
23 Palaniammal 
 
51 7 146 59 27.7 38.6 172 42 108 22 110 
24 Asimbegam 
 
50 8 159 39 15.4 17.4 166 28 101 28 140 
25 Kaliammal 
 
57 7 149 47 21.2 19.1 156 34 91 31 155 
26 Jothi 
 
55 7 149 47 21.2 24.6 215 36 145 34 170 
27 Vasuki 
 
51 8 166 69 25 27.7 178 32 108 38 190 
28 Meenatchi 
 
51 9 169 84 29.4 24.8 225 38 158 26 130 
29 Jeyakumari 
 
50 8 174 64 21.1 21.4 186 34 124 28 140 
30 Muneesmeena 
 
50 8 168 70 24.8 23.2 172 40 109 23 115 
Sl.no NAME 
 
AGE 
(years) 
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1 Renganayagi 
 
55 12 162 74 28.2 22.4 189 38 130.8 19.2 101 
2 Perumalammal 
 
60 14 152 68 29.4 24.88 161 40 94.7 18.5 96 
3 Sulochana 
 
55 11 155 56 23.3 23.04 167 37 141.6 16 92 
4 Mariyammal 
 
59 12 143 59 28.9 10.87 214 24 175 15 75 
5 Devaki 
 
54 11 146 62 29.1 5 199.2 31 146.2 22 125 
6 Fatima 
 
58 12 151 72 31.6 5 145 37 82 26 130 
7 Saroja 
 
58 13 153 67 28.6 5 184 27 134 23 115 
8 Madathi 
 
58 14 155 72 30 16.9 229 34 168 27 135 
9 Renganayaki 
 
57 12 150 81 36 15.06 152 28 81.8 42.2 181 
10 Kalavathi 
 
59 15 147 67 31 8.22 190 38 139.7 12.3 120 
11 Vijayalakshmi 
 
57 12 149 75 33.8 5.74 160 38 99.7 22.3 111.5 
12 Rahmathbeevi 
 
60 14 150 55 24.4 11.3 170 31 122 17 125 
13 Pushpavalli 
 
59 12 152 65 28.1 13.4 196 33 131.8 31.2 156 
14 Savithri 
 
60 12 140 58 29.6 15 216 32 154 21 150 
15 Otahammal 
 
59 11 164 65 24.2 26 146 25 129 19.2 120 
16 Ponrakku 
 
55 13 145 58 27.6 18.2 223 27 175 21 105 
17 Kamatchi 
 
58 12 151 59 25.9 24 198 30 113 20.5 165 
18 Stella 
 
60 15 148 80 36.5 20.8 169 26 109 22 170 
19 Karuppayammal 
 
60 11 152 65 28.1 16.4 188 34 132 22 110 
20 Anitha 
 
59 12 150 62 27.6 11.2 181 27 148 34 170 
21 Saraswathi 
 
55 13 157 87 35.3 17.3 193 35 135 23 115 
22 Selvi 
 
58 16 160 58 22.7 21.3 170 35 110 18.6 120 
23 Shanthi 
 
54 14 150 54 24 25.6 163 30 129 18.2 95 
24 Rani 
 
60 11 148 60 27.4 14.2 199 35 120 44 220 
25 Muthupetchi 
 
58 12 143 55 26.9 16.8 186 30 127 29 145 
26 Chithrakani 
 
54 13 146 59 27.7 15.2 201 40 132 29 145 
27 Karpagam 
 
57 11 151 62 27.2 23.4 180 33 113 14 90 
28 Rukmani 
 
58 12 154 68 28.7 28.9 208 34 130 24 126 
29 Meenambikai 
 
55 14 156 64 26.3 18.2 173 36 103 34 170 
30 
 
Kalamani 
 
57 12 153 60 25.6 26 171 38 125 20.2 120 
